Hikma Pharmaceuticals Share News (HIK)

London open: Stocks bounce even as analysts warn on emerging markets

(ShareCast News) - The selling pressure on stocks abated as investors waited on the US Federal Reserve's policy announcement on Wednesday, but worries regarding the outlook for China, Greece and the possibility of interest rate increases were still very much on investors' minds. As of 08:47 the FTSE

LONDON MARKET MID-MORNING: Pound Surges After UK GDP Comes In-Line

WINNERS & LOSERS SUMMARY: Zurich Interest Sends RSA Insurance Higher

Hikma Pharmaceuticals acquires US labs in $2.25bn deal

(ShareCast News) - Drug developer Hikma Pharmaceuticals signed a deal to buy two firms from Boehringer Ingelheim in transactions worth a total of $2.25bn. FTSE 100 listed Hikma planned to buy Roxane Laboratories and associated company Boehringer Ingelheim Roxane in a cash and shares deal that would

BUZZ-Hikma: best day in 7 months after announcing Boehringer deal

** Hikma rises 6.7 pct after agreeing to buy Boehringer's specialty generics business for $2.65 bln in cash ** Valuation based on new Hikma shares priced at £23.50 ** Best day for stock since January 2015 ** Among top risers and most traded by average volumes on Stoxx 600 <p

LONDON BRIEFING: Royal Mail Shares Hit By Ofcom Accusation

UPDATE 1-Hikma to buy Boehringer's U.S. generics unit for $2.65 bln

(Adds details) July 28 (Reuters) - Hikma Pharmaceuticals Plc said it would buy German drugmaker Boehringer Ingelheim's U.S. specialty generic drugs business for about $2.65 billion in cash and stock to bolster its presence in the United States. Hikma said it will pay about $1.18 billi

Hikma to buy Boehringer's U.S. generics unit for $2.65 bln

July 28 (Reuters) - Hikma Pharmaceuticals Plc said it would buy German drugmaker Boehringer Ingelheim's U.S. specialty generic drugs business for about $2.65 billion in cash and stock to bolster its presence in the United States. Hikma said it will pay about $1.18 billion in cash and issue

Hikma Pharmaceuticals To Acquire Roxane Units For USD2.65 Billion (ALLISS)

LONDON MARKET CLOSE: Stocks Mixed Amid Puzzling Greek Offer Exchange

WINNERS & LOSERS: Tesco And Sainsbury's Beaten By Morrisons

TOP NEWS: UK Economic Growth Revised Up In First Quarter

LONDON BRIEFING: Shares Ignore Positive Asian Session To Open Lower

PRESS: Hikma, Mallinckrodt Bid For Boehringer Assets - Bloomberg

Boehringer's Roxane Labs draws bid from Hikma, Mallinckrodt- Bloomberg

June 29 (Reuters) - Jordan's Hikma Pharmaceuticals Plc has emerged as a bidder for German drugmaker Boehringer Ingelheim's generics unit Roxane Labs, Bloomberg reported, citing people familiar with the matter. Other bidders for the U.S.-based Boehringer unit include Mallinckrodt Plc and Pe